About Ardelyx
Ardelyx is a company based in Fremont (United States) founded in 2007 by Peter G Schultz. Ardelyx has raised $61.1 million across 8 funding rounds from investors including Western Alliance Bank, RA Capital and SLR Investment Corp. The company has 395 employees as of December 31, 2024. Ardelyx operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, DermBiont, Cosmo Pharmaceuticals and Alcresta, among others.
- Headquarter Fremont, United States
- Employees 395 as on 31 Dec, 2024
- Founders Peter G Schultz
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ardelyx, Inc.
-
Annual Revenue
$333.62 M (USD)168.06as on Dec 31, 2024
-
Net Profit
-$39.14 M (USD)40.76as on Dec 31, 2024
-
EBITDA
-$25.89 M (USD)58.24as on Dec 31, 2024
-
Total Equity Funding
$61.1 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
Western Alliance Bank
& 10 more
-
Employee Count
395
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ardelyx
Ardelyx is a publicly listed company on the NASDAQ with ticker symbol ARDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Ardelyx
Unlock access to complete
Leadership Team
37 people
Sales and Marketing
8 people
Human Resources and Administration
7 people
Legal and Compliance
6 people
Operations Team
6 people
Software Development Team
4 people
Finance and Accounting
3 people
Product Management Team
2 people
Unlock access to complete
Funding Insights of Ardelyx
Ardelyx has successfully raised a total of $61.1M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ardelyx
Ardelyx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Western Alliance Bank, RA Capital and SLR Investment Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
Debt and equity investments are offered by the firm.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Ardelyx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ardelyx
Investment portfolio details for Ardelyx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ardelyx
Detailed financials for Ardelyx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ardelyx Comparisons
Peer comparison for Ardelyx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ardelyx
Ardelyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, DermBiont, Cosmo Pharmaceuticals and Alcresta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal diseases are developed and provided.
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
Detailed competitors of Ardelyx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ardelyx
Complete news archive for Ardelyx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ardelyx
Ardelyx was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Ardelyx is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Mike Raab is the current CEO of Ardelyx.
Ardelyx is a funded company, having raised a total of $61.1M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Ardelyx is 395.
Annual revenue of Ardelyx is $333.62M as on Dec 31, 2024.
Ardelyx was founded in 2007 and is based in Fremont, United States. Focus is placed on developing therapeutics targeting the gastrointestinal tract for conditions including cardio-renal, GI, and metabolic diseases. The lead product, Tenapanor, is advanced as a sodium transport inhibitor for irritable bowel syndrome with constipation and hyperphosphatemia in dialysis patients. Additional efforts involve RDX002 for hyperkalemia treatment in kidney and heart disease patients.
Ardelyx's top competitors include Ironwood Pharma, RedHill Biopharma and Inozyme Pharma.
Yes, Ardelyx is publicly traded on NASDAQ under the ticker symbol ARDX.
Ardelyx has 11 investors. Key investors include Western Alliance Bank, RA Capital, SLR Investment Corp, Kyowa Kirin, and HealthCare Royalty Partners.
The ticker symbol of Ardelyx is ARDX on NASDAQ.